Nektar Therapeutics raises $30M through a private placement with TCGX at $1.20/share.
Nektar Therapeutics (NKTR) announced a $30M share placement with TCGX, an institutional accredited investor, offering 25M shares of common stock in a private placement financing (PIPE) at $1.20/share, with an 80% premium over the 30-day VWAP. The pre-funded warrant has no expiration date. The deal is expected to close on or before March 6, 2024, subject to customary closing conditions.
March 04, 2024
4 Articles